These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1468 related articles for article (PubMed ID: 25572091)

  • 1. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
    Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
    Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
    J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
    Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
    Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?
    Abramyuk A; Tokalov S; Zöphel K; Koch A; Szluha Lazanyi K; Gillham C; Herrmann T; Abolmaali N
    Radiother Oncol; 2009 Jun; 91(3):399-404. PubMed ID: 19168248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
    Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.